Antimoniato de meglumina genéricopara el tratamiento de la leishmaniasis cutánea en Colombia
Palabras clave:
Leishmaniasis, Leishmaniasis cutánea, antimoniales pentavalentes, meglumina, antimoniato de meglumina, terapéuticaResumen
El antimoniato de meglumina es la sal de antimonio pentavalente que se emplea en Colombia para el tratamiento de la leishmaniasis cutánea con una e!ectividad reportada entre 94% y 81 % y con un perfil de seguridad conocido. Actualmente se encuentra dis ponible una segunda presentación de meglumina producida en Argentina y en el presente reporte se demuestra que tiene una efectividad de 92% y que los eventos adversos son similares en intensidad y frecuencia a los reportados con la meglumina de Aventis. Los casos anuales de leishmaniasis se han incrementado sustancialmente, por lo cual la posibili dad de reducir los costos del tratamiento hace atractiva esta segunda opción, ya que en los países donde está disponible este genérico su precio es significativamente menor.
Biografía del autor/a
Jaime Soto, Cibic, Centro de Investigaciones Bioclinicas
Cibic, Centro de Investigaciones Bioclínicas,
Calle 60A No. 5 - 54 Of. 201-B, Bogotá.
Julia Toledo, Cibic, Centro de Investigaciones Bioclinicas
Cibic, Centro de Investigaciones Bioclínicas,
Calle 60A No. 5 - 54 Of. 201-B, Bogotá.
Paula Soto, Cibic, Centro de Investigaciones Bioclinicas
Cibic, Centro de Investigaciones Bioclínicas,
Calle 60A No. 5 - 54 Of. 201-B, Bogotá.
Patricia Gutièrrez, Fundaciòn Fader
-
Fundación Fader, Calle 60 A No. 5 - 54 Of. 201-A, Bogotá.
Ricardo Herrera, Fundación Fader
-
Fundación Fader, Calle 60 A No. 5 - 54 Of. 201-A, Bogotá.
Jonathan Berman, AB Foundation for Medical Research
3. AB Foundation for Medica/ Research, 14220 Poindexter Ln,
North Bethesda, MD, USA
Referencias bibliográficas
1. Davies C, Reithinger R, Campbell-Lendrum D, Feliciangeli D, BorgesR, et al. The epidemiology and control ofleishmaniasis in Andean countries. Cad Saude Publica 2000;16: 925-50.
https://doi.org/10.1590/S0102-311X2000000400013
2. Soto J, Valda-Rodriquez L, Toledo J, Vera-Navarro L, Luzz M, Monasterios-Torrico H, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg 2004;71: 577-81.
https://doi.org/10.4269/ajtmh.2004.71.577
3. MinisteriodeSalud,Colombia,2000.Guíasdeatención de las leishmaniasis, disponible en: http://www.metro- salud.gov.co/Paginas/Protocolos/MinSalud/guias/35- LEISHMANIASIS.htm
4.Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Passer RA Jr, Magill AJ, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clinlnfect Dis 1998;27: 1457-64.
https://doi.org/10.1086/515027
5.Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, et al. Efficacy of 28-day and 40- day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosa! leishmaniasis. Am J Trop Med Hyg 1994;51: 77-82.
https://doi.org/10.4269/ajtmh.1994.51.77
6. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized con- trolled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990;42: 43-50.
https://doi.org/10.4269/ajtmh.1990.42.43
7. Navin TR, Arana BA, Arana FE, Berman JO, Chajon JF. Placebo-controlled clinical trial of sodium stiboglu- conate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J lnfect Dis 1992;165:528-34.
https://doi.org/10.1093/infdis/165.3.528
8. RomeroGA,GuerraMV,PaesMG,MacedoVO.Com- parison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001;65: 456-65.
https://doi.org/10.4269/ajtmh.2001.65.456
9. SotoJ.ToledoJ,VegaJ,BermanJ.Shortreport:Effica- cy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis. Am J Trop Med Hyg 2005;72: 412-3.
https://doi.org/10.4269/ajtmh.2005.72.421
10. Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001;79: 388-93.
11. RitmeijerK,VeekenH,MelakuY,LealG,AmsaluR,Sea- man J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate and equivalent: HIV coinfected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001;95:668-72.
https://doi.org/10.1016/S0035-9203(01)90110-5
12. VeekenH,RitmeijerK,SeamanJ,DavidsonR.Arancio- mized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med lnt Health 2000;5: 312-7.
https://doi.org/10.1046/j.1365-3156.2000.00555.x
13. ProgramCTC.2002.CommonToxicityCriteria.Rock- ville, MD.: National Cancer lnstitute.
14. Soto J, Toledo J, Soto P, Vega J, Casas L, Herrera R, et al. Respuesta a antimoniales pentavalentes para el tra- tamiento de la leishmaniasis cutánea en Colombia. Rev Asoc Col Dermatol Cir Dermatol 2005; 13(1):39-44.
15. Velez 1, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al. lnefficacy of allopurinol for Colom- bian cutaneous leishmaniasis: a randomized, controlled trial. Ann lntern Med 1997; 126 232-6.
https://doi.org/10.7326/0003-4819-126-3-199702010-00010
16. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treat- ment failure in children in a randomized clinical trial with 1O and 20 days of meglumine antimonate for Colombian cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001;64:187-93.
https://doi.org/10.4269/ajtmh.2001.64.187
17. SundarS,MoreD,SinghM,SinghV,SharmaS,Makha- ria A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the lndian epidemic. Clin lnfect Dis 2000;31: 11047.
https://doi.org/10.1086/318121
18. Yardley V, Croft S, De Doncker S, Dujardin J, Koirala S, Rijal S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005;73:272-275.
https://doi.org/10.4269/ajtmh.2005.73.272
19. Gasser RA, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JO. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin lnfect Dis 1994; 18: 83-90.
https://doi.org/10.1093/clinids/18.1.83
20. Sundar S. Drug resistance in lndian visceral leishma- niasis. Trop Med lnt Health 2001; 6(11):849-54.
https://doi.org/10.1046/j.1365-3156.2001.00778.x
21. HepburnNC,Siddique1,HowieAF,BeckettGJ,Hayes PC. Hepatotoxicity of sodium stibogluconate therapy forAmericancutaneousleishmaniasis. TransRoySoc Trop Med Hyg 1994;88:453-5.
https://doi.org/10.1016/0035-9203(94)90432-4
https://doi.org/10.1590/S0102-311X2000000400013
2. Soto J, Valda-Rodriquez L, Toledo J, Vera-Navarro L, Luzz M, Monasterios-Torrico H, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg 2004;71: 577-81.
https://doi.org/10.4269/ajtmh.2004.71.577
3. MinisteriodeSalud,Colombia,2000.Guíasdeatención de las leishmaniasis, disponible en: http://www.metro- salud.gov.co/Paginas/Protocolos/MinSalud/guias/35- LEISHMANIASIS.htm
4.Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Passer RA Jr, Magill AJ, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clinlnfect Dis 1998;27: 1457-64.
https://doi.org/10.1086/515027
5.Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, et al. Efficacy of 28-day and 40- day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosa! leishmaniasis. Am J Trop Med Hyg 1994;51: 77-82.
https://doi.org/10.4269/ajtmh.1994.51.77
6. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized con- trolled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990;42: 43-50.
https://doi.org/10.4269/ajtmh.1990.42.43
7. Navin TR, Arana BA, Arana FE, Berman JO, Chajon JF. Placebo-controlled clinical trial of sodium stiboglu- conate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J lnfect Dis 1992;165:528-34.
https://doi.org/10.1093/infdis/165.3.528
8. RomeroGA,GuerraMV,PaesMG,MacedoVO.Com- parison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001;65: 456-65.
https://doi.org/10.4269/ajtmh.2001.65.456
9. SotoJ.ToledoJ,VegaJ,BermanJ.Shortreport:Effica- cy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis. Am J Trop Med Hyg 2005;72: 412-3.
https://doi.org/10.4269/ajtmh.2005.72.421
10. Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001;79: 388-93.
11. RitmeijerK,VeekenH,MelakuY,LealG,AmsaluR,Sea- man J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate and equivalent: HIV coinfected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001;95:668-72.
https://doi.org/10.1016/S0035-9203(01)90110-5
12. VeekenH,RitmeijerK,SeamanJ,DavidsonR.Arancio- mized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med lnt Health 2000;5: 312-7.
https://doi.org/10.1046/j.1365-3156.2000.00555.x
13. ProgramCTC.2002.CommonToxicityCriteria.Rock- ville, MD.: National Cancer lnstitute.
14. Soto J, Toledo J, Soto P, Vega J, Casas L, Herrera R, et al. Respuesta a antimoniales pentavalentes para el tra- tamiento de la leishmaniasis cutánea en Colombia. Rev Asoc Col Dermatol Cir Dermatol 2005; 13(1):39-44.
15. Velez 1, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al. lnefficacy of allopurinol for Colom- bian cutaneous leishmaniasis: a randomized, controlled trial. Ann lntern Med 1997; 126 232-6.
https://doi.org/10.7326/0003-4819-126-3-199702010-00010
16. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treat- ment failure in children in a randomized clinical trial with 1O and 20 days of meglumine antimonate for Colombian cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001;64:187-93.
https://doi.org/10.4269/ajtmh.2001.64.187
17. SundarS,MoreD,SinghM,SinghV,SharmaS,Makha- ria A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the lndian epidemic. Clin lnfect Dis 2000;31: 11047.
https://doi.org/10.1086/318121
18. Yardley V, Croft S, De Doncker S, Dujardin J, Koirala S, Rijal S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005;73:272-275.
https://doi.org/10.4269/ajtmh.2005.73.272
19. Gasser RA, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JO. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin lnfect Dis 1994; 18: 83-90.
https://doi.org/10.1093/clinids/18.1.83
20. Sundar S. Drug resistance in lndian visceral leishma- niasis. Trop Med lnt Health 2001; 6(11):849-54.
https://doi.org/10.1046/j.1365-3156.2001.00778.x
21. HepburnNC,Siddique1,HowieAF,BeckettGJ,Hayes PC. Hepatotoxicity of sodium stibogluconate therapy forAmericancutaneousleishmaniasis. TransRoySoc Trop Med Hyg 1994;88:453-5.
https://doi.org/10.1016/0035-9203(94)90432-4
Cómo citar
1.
Soto J, Toledo J, Soto P, Gutièrrez P, Herrera R, Berman J. Antimoniato de meglumina genéricopara el tratamiento de la leishmaniasis cutánea en Colombia. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de febrero de 2007 [citado 18 de abril de 2024];15(1):29-34. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/437
Descargas
Los datos de descargas todavía no están disponibles.
Descargas
Publicado
2007-02-01
Cómo citar
1.
Soto J, Toledo J, Soto P, Gutièrrez P, Herrera R, Berman J. Antimoniato de meglumina genéricopara el tratamiento de la leishmaniasis cutánea en Colombia. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de febrero de 2007 [citado 18 de abril de 2024];15(1):29-34. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/437
Número
Sección
Artículo Original
